Sam Brusco, Associate Editor01.03.23
ReCor Medical has appointed Lara Barghout as its new president and CEO. She will lead the global commercialization of ReCor’s Paradise ultrasound renal denervation (uRDN) system to treat hypertension.
Barghout joins the company from Siemens Healthineers, where she served as senior VP and head of Advanced Therapies, leading the North American image-guided therapy business. Before Siemens, she had several roles at Terumo Cardiovascular, rising to become senior VP of global commercial operations.
“I am honored to lead the extraordinary team at ReCor at an exciting time in the company’s growth,” Barghout told the press. “High blood pressure is a leading contributor to cardiovascular disease burden worldwide, resulting in increased patient risk and higher costs to health systems. I look forward to leading our focus to advance uRDN as a treatment for hypertension and the global commercialization of the Paradise uRDN System. We believe our Paradise uRDN technology to be a true game changer in improving hypertension therapy, with the potential to offer a new option for physicians to help improve blood pressure outcomes for their patients on a global scale.”
She succeeds Andrew Weiss, who joined ReCor in 2013 and led the company during development of its Paradise uRDN system from early clinical trials, to acquisition of the company by Otsuka Medical Devices in 2018, to RADIANCE trial successes and recent submission to the FDA for premarket approval.
“We are delighted to name Barghout president and CEO of ReCor. She is a highly experienced leader with a track record of commercial success across a range of medical device businesses, coupled with extensive experience in global leadership,” said Noriko Tojo, executive director of Otsuka Holdings Co., Ltd. and president of Otsuka Medical Devices. “We are very excited for Ms. Barghout to lead ReCor into its next phase of global growth. Her deep commercial experience and adept leadership make her ideal to build on the technology development and clinical trial successes of the ReCor team, guiding the business to realize its therapeutic and commercial potential. I would like to thank Andy for his outstanding leadership and countless contributions over the past 10 years.”
Paradise uRDN has a CE mark for hypertension and is investigational in the U.S. and Japan.
Barghout joins the company from Siemens Healthineers, where she served as senior VP and head of Advanced Therapies, leading the North American image-guided therapy business. Before Siemens, she had several roles at Terumo Cardiovascular, rising to become senior VP of global commercial operations.
“I am honored to lead the extraordinary team at ReCor at an exciting time in the company’s growth,” Barghout told the press. “High blood pressure is a leading contributor to cardiovascular disease burden worldwide, resulting in increased patient risk and higher costs to health systems. I look forward to leading our focus to advance uRDN as a treatment for hypertension and the global commercialization of the Paradise uRDN System. We believe our Paradise uRDN technology to be a true game changer in improving hypertension therapy, with the potential to offer a new option for physicians to help improve blood pressure outcomes for their patients on a global scale.”
She succeeds Andrew Weiss, who joined ReCor in 2013 and led the company during development of its Paradise uRDN system from early clinical trials, to acquisition of the company by Otsuka Medical Devices in 2018, to RADIANCE trial successes and recent submission to the FDA for premarket approval.
“We are delighted to name Barghout president and CEO of ReCor. She is a highly experienced leader with a track record of commercial success across a range of medical device businesses, coupled with extensive experience in global leadership,” said Noriko Tojo, executive director of Otsuka Holdings Co., Ltd. and president of Otsuka Medical Devices. “We are very excited for Ms. Barghout to lead ReCor into its next phase of global growth. Her deep commercial experience and adept leadership make her ideal to build on the technology development and clinical trial successes of the ReCor team, guiding the business to realize its therapeutic and commercial potential. I would like to thank Andy for his outstanding leadership and countless contributions over the past 10 years.”
Paradise uRDN has a CE mark for hypertension and is investigational in the U.S. and Japan.